BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36480431)

  • 21. Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer.
    Buderath P; Schwich E; Jensen C; Horn PA; Kimmig R; Kasimir-Bauer S; Rebmann V
    Front Oncol; 2019; 9():1015. PubMed ID: 31681568
    [No Abstract]   [Full Text] [Related]  

  • 22. Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility.
    Santoso B; Sa'adi A; Dwiningsih SR; Tunjungseto A; Widyanugraha MYA; Mufid AF; Rahmawati NY; Ahsan F
    Am J Reprod Immunol; 2020 Oct; 84(4):e13296. PubMed ID: 32593225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
    Zhou J; Mahoney KM; Giobbie-Hurder A; Zhao F; Lee S; Liao X; Rodig S; Li J; Wu X; Butterfield LH; Piesche M; Manos MP; Eastman LM; Dranoff G; Freeman GJ; Hodi FS
    Cancer Immunol Res; 2017 Jun; 5(6):480-492. PubMed ID: 28522460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
    Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
    Chivu-Economescu M; Herlea V; Dima S; Sorop A; Pechianu C; Procop A; Kitahara S; Necula L; Matei L; Dragu D; Neagu AI; Bleotu C; Diaconu CC; Popescu I; Duda DG
    Gastric Cancer; 2023 Nov; 26(6):934-946. PubMed ID: 37668884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. sPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance.
    Han S; Zhang Y; Yuan J; Wu Y; Zhou Y; Zhou Y; Li X; Zhou S
    Cytokine; 2024 Apr; 176():156532. PubMed ID: 38330638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas.
    Liu S; Zhu Y; Zhang C; Meng X; Sun B; Zhang G; Fan Y; Kang X
    Front Oncol; 2020; 10():9. PubMed ID: 32038986
    [No Abstract]   [Full Text] [Related]  

  • 28. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
    Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
    Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism.
    Raftery MJ; Abdelaziz MO; Hofmann J; Schönrich G
    Front Immunol; 2018; 9():2560. PubMed ID: 30559738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis.
    Ding Y; Sun C; Hu L; Xiong S; Zhai Z
    Ann Hematol; 2023 Sep; 102(9):2425-2434. PubMed ID: 37382610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Levels and Clinical Significances of sPD-1 and sPD-L1 in Peripheral Blood of Lymphoma Patients].
    Liu XL; He P; Lei J; Zou LX; Peng L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1733-1738. PubMed ID: 38071053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
    Carosio R; Fontana V; Mastracci L; Ferro P; Grillo F; Banelli B; Canessa PA; Dessanti P; Vigani A; Morabito A; Pfeffer U; Poggi A; Roncella S; Pistillo MP
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma.
    Guo X; Wang J; Jin J; Chen H; Zhen Z; Jiang W; Lin T; Huang H; Xia Z; Sun X
    Transl Oncol; 2018 Jun; 11(3):779-785. PubMed ID: 29698935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
    Luo L; Shu M; Li S; Cai Y
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Soluble programmed death-1 and soluble programmed death ligand 1 protein expression and immune status in patients with recurrent aphthous ulcer].
    Nan J; Liang L; Li L; Xiaoqin S; Xing J; Yang C
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2017 Jun; 35(3):286-290. PubMed ID: 28675014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
    Kawakami H; Sunakawa Y; Inoue E; Matoba R; Noda K; Sato T; Suminaka C; Yamaki M; Sakamoto Y; Kawabata R; Ishiguro A; Akamaru Y; Kito Y; Yabusaki H; Matsuyama J; Takahashi M; Makiyama A; Hayashi H; Chamoto K; Honjo T; Nakagawa K; Ichikawa W; Fujii M
    Eur J Cancer; 2023 May; 184():10-20. PubMed ID: 36889037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
    El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
    Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.
    Shen H; Ji Y; Zhou D; Zhang Y; Wang W; Sun J; Zhang W
    Hematology; 2019 Dec; 24(1):392-398. PubMed ID: 30890046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours.
    Mair MJ; Pajenda S; Ilhan-Mutlu A; Steindl A; Kiesel B; Widhalm G; Dieckmann K; Feldmann K; Hainfellner J; Marosi C; Müllauer L; Wagner L; Preusser M; Berghoff AS
    ESMO Open; 2020 Nov; 5(6):e000863. PubMed ID: 33184096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.